000			01588 a2200433 4500
005			20250515121423.0
264		0	_c20081006
008			200810s 0 0 eng d
022			_a1421-9913
024	7		_a10.1159/000131893 _2doi
040			_aNLM _beng _cNLM
100	1		_aEncarnacion, Elmyra V
245	0	0	_aLevodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. _h[electronic resource]
260			_bEuropean neurology _c2008
300			_a57-66 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAged
650	0	4	_aAnimals
650	0	4	_aAntiparkinson Agents _xadministration & dosage
650	0	4	_aBasal Ganglia _xdrug effects
650	0	4	_aCorpus Striatum _xdrug effects
650	0	4	_aDeep Brain Stimulation
650	0	4	_aDopamine _xphysiology
650	0	4	_aDopamine Agonists _xadverse effects
650	0	4	_aDrug Administration Schedule
650	0	4	_aDyskinesia, Drug-Induced _xetiology
650	0	4	_aExcitatory Amino Acid Antagonists _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aLevodopa _xadministration & dosage
650	0	4	_aMulticenter Studies as Topic
650	0	4	_aParkinson Disease _xcomplications
650	0	4	_aQuality of Life
650	0	4	_aReceptors, Glutamate _xphysiology
650	0	4	_aSeverity of Illness Index
650	0	4	_agamma-Aminobutyric Acid _xphysiology
700	1		_aHauser, Robert A
773	0		_tEuropean neurology _gvol. 60 _gno. 2 _gp. 57-66
856	4	0	_uhttps://doi.org/10.1159/000131893 _zAvailable from publisher's website
999			_c17975290 _d17975290